Stroke prevention with oral anticoagulants (OACs) is the cornerstone for the management of atrial fibrillation (AF). However, data about the use of OACs among patients ≥90 years of age are limited. We aimed to investigate the risk of ischemic stroke and intracranial hemorrhage (ICH) and the net clinical benefit of OAC treatment for very elderly patients with AF (≥90 years of age).
A trial fibrillation (AF) is a disease of the elderly, with an increasing prevalence and incidence with age. Indeed, 10% of the general population ≥80 years of age have AF, with an exponential rise in more elderly patients.
Stroke prevention is the priority of modern AF management, and effective stroke prevention requires longterm use of oral anticoagulants (OACs). Evidence for the long-term use of OACs comes from randomized controlled trials (RCTs) convincingly demonstrating that warfarin reduces stroke/systemic embolism by 67%, ischemic stroke by 65%, and all-cause mortality by 26% compared with placebo or control. 1 Aspirin has a nonsignificant reduction in stroke/systemic embolism or mortality compared with placebo or control.
Nonetheless, elderly patients were underrepresented in these historical RCTs of 2 decades ago. In the BAFTA trial (Birmingham Atrial Fibrillation Treatment of the Aged Study), which specifically investigated elderly patients with AF ≥75 years of age in primary care, 973 patients were randomized to warfarin or aspirin 75 mg, and the trial convincingly showed that warfarin significantly reduced thromboembolism by >50%, with no significant difference between warfarin and aspirin for major bleeding or intracranial bleeding. 2 In the small WASPO trial (Warfarin Versus Aspirin for Stroke Prevention in Octogenarians With AF) conducted in octogenarians, there was numerically no difference in stroke between warfarin and aspirin, but there was a significantly greater rate of adverse safety outcomes (including bleeding) in aspirin-treated patients. 3 The very elderly patients with AF are even less represented in RCTs. For example, BAFTA only included ≈20% of those ≥85 years of age. 2 Such patients are often denied OAC because of physician concerns about the inability to cope with warfarin monitoring (although nonvitamin K antagonist OACs [NOACs] may overcome this excuse) or safety issues with bleeding risk. Also, the lack of adequate RCT evidence in this population is another factor, dissuading OAC use with vitamin K antagonists or NOACs. Furthermore, whether AF is still associated with an increased risk of ischemic stroke among patients ≥90 years of age is also unclear.
In this nationwide cohort study, the principal goals are as follows: (1) to compare the risk of ischemic stroke and intracranial hemorrhage (ICH) in patients with AF ≥90 years of age to those without AF, (2) to explore stroke and bleeding outcomes and the net clinical benefit (NCB) of warfarin treatment for patients with AF ≥90 years of age, and (3) to compare the risks of stroke and bleeding among patients with AF ≥90 years of age treated with warfarin or NOACs. We hypothesized that AF was still associated with an increased risk of ischemic stroke even in the very elderly population, and warfarin treatment was associated with a lower risk of ischemic stroke and a positive NCB. Also, we hypothesized that NOACs could still have a lower risk of ICH compared with warfarin among patients ≥90 years of age.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Database
This study used the National Health Insurance Research Database (NHIRD) provided by the Taiwan National Health Research Institutes and Health and Welfare Data Science Center, Ministry of Health and Welfare, Taiwan. The National Health Insurance system is a mandatory universal health insurance program that offers comprehensive medical care coverage to all Taiwanese residents. NHIRD consists of detailed healthcare data from >23 million enrollees, representing >99% of Taiwan's population. In this cohort dataset, the patients' original identification numbers have been encrypted to protect their privacy, but the encrypting procedure was consistent so that a linkage of the claims belonging to the same patient was feasible within the National Health Insurance database and can be followed continuously. The
Clinical Perspective
What Is New?
• Data on the risks of ischemic stroke and intracranial hemorrhage and the use of oral anticoagulants among patients with atrial fibrillation (AF) ≥90 years of age are limited.
• Even among the very elderly (≥90 years of age) patients, AF was associated with an increased risk of ischemic stroke compared with patients without AF.
• Among patients with AF ≥90 years of age, warfarin use was associated with a lower risk of ischemic stroke, with no difference in intracranial hemorrhage risk compared with nonwarfarin treatment.
• The use of warfarin was associated with a positive net clinical benefit compared with being untreated or receiving antiplatelet therapy.
• Compared with warfarin, nonvitamin K antagonist oral anticoagulants were associated with a lower risk of intracranial hemorrhage (by 68% in a competing risk model), with no difference in risk of ischemic stroke.
What Are the Clinical Implications?
• Among patients with AF ≥90 years of age, the use of warfarin was associated with a lower risk of ischemic stroke and positive net clinical benefit considering the risk of intracranial hemorrhage.
• Oral anticoagulants may still be considered as thromboprophylaxis for elderly patients, with nonvitamin K antagonist oral anticoagulants being the more favorable choice.
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Study Design
In the present study, 2 study cohorts identified from the NHIRD during different timing periods were utilized for different analyses ( Figure 1 ): (1) Era without NOACs (1996-2011): the risks of ischemic stroke and ICH of patients with AF ≥90 years of age were compared with those without AF. In addition, stroke and bleeding outcomes and the NCB of warfarin treatment were analyzed. (2) Era with NOACs (2012 NOACs ( -2015 : the risks of ischemic stroke and ICH for patients with AF ≥90 years of age treated with NOACs were compared with those treated with warfarin.
Study Population in the Era Without NOACs (1996-2011)
From January 1, 1996, to December 31, 2011, a total of 15 756 patients with AF ≥90 years of age were identified and divided into 3 groups based on the medications used for stroke prevention ( Figure 1 ). AF was diagnosed using the International Classification of Diseases, Ninth Revision, Clinical Modification codes (427.31) registered by the physicians responsible for the treatments of patients. To ensure the accuracy of diagnosis, we defined patients with AF only when it was a discharge diagnosis or confirmed ≥2 times in the outpatient department. The diagnostic accuracy of AF using this definition in NHIRD has been validated previously. 13 To understand whether AF is still associated with an increased risk of ischemic stroke among patients ≥90 years of age, for each patient with AF, an age-and sex-matched patient without AF was identified from 1 million beneficiaries randomly sampled from Taiwan NHIRD (n=15 756). Among these patients without AF, 14 658 of them did not receive any antiplatelet or anticoagulant agent, and their risks of ischemic stroke and ICH were compared to those of patients with AF without antithrombotic therapy (n=11 064) (Figure 1 ).
Study Population in the Era With NOACs (2012-2015)
Because NOACs were only available in Taiwan from 2012, the comparisons of warfarin and NOACs were performed among patients with AF ≥90 years of age identified from the NHIRD between 2012 and 2015. A total of 768 and 978 newly diagnosed patients with AF ≥90 years of age received warfarin and NOACs for stroke prevention, respectively ( Figure 1 ). The risks of ischemic stroke, ICH, and major bleeding were compared between these 2 treatment groups.
Calculation of Score and Definition of Clinical End Point
The CHA 2 DS 2 -VASc score (congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65-74, female) was calculated for each patient by assigning 1 point each for being between 65 and 74 years of age and having a history of hypertension, diabetes mellitus, recent cardiac failure, vascular disease (myocardial infarction or peripheral artery disease), and female sex, and 2 points each for having a history of stroke/transient ischemic attack, or being ≥75 years of age. 14 The clinical end point was the occurrence of ischemic stroke, with concomitant imaging studies of the brain, including computed tomography or magnetic resonance imaging. The accuracy of diagnosis of ischemic stroke in Taiwan's NHIRD has been reported to be ≈94%. 15 Another validation study also demonstrated that the diagnostic accuracy of ischemic stroke in NHIRD was high, with the positive predictive value and sensitivity of 88.4% and 97.3%, respectively. 16 The safety end point was the occurrence of ICH with concomitant imaging studies of the brain, necessitating admissions to intensive care units. Each end point (ischemic stroke or ICH) was analyzed independently of the other without being censored. Major bleeding was defined as ICH or bleeding from the gastrointestinal, genitourinary, or respiratory tract requiring hospitalization.
Analysis of NCB
The NCB for the use of warfarin or antiplatelet therapy compared with no treatment was calculated using the following formula: (ischemic stroke rate on no treatment minus ischemic stroke rate on antithrombotic therapies) -weighting factor × (ICH rate on antithrombotic therapies minus ICH rate on no treatment). The weighting factor reflects the relative impact, in terms of death and disability, of an ICH while receiving warfarin or antiplatelet agents versus experiencing an ischemic stroke while on no treatment. [17] [18] [19] We used the marginal prediction approach to calculate the adjusted rates of ischemic stroke and ICH in each treatment group, and the 95% confidence intervals (CIs) were analyzed by bootstrapping. The NCBs were calculated from the differences of the adjusted rates of ischemic stroke and ICH in the present study based on the weights previously produced and reported by Singer et al, 17 Connolly et al, 18 and Lip et al. 19 The 95% CIs of NCBs were obtained by bootstrapping. A positive NCB favors treatment (ie, warfarin) when compared with no treatment.
Propensity Match Analysis
We performed propensity score-matched analyses for 2 kinds of comparisons among patients with AF ≥90 years of age: antiplatelet agents versus no antithrombotic therapy and warfarin versus no antithrombotic therapy. We calculated propensity scores for the likelihoods of receiving antiplatelet agents and warfarin compared with no antithrombotic therapy by multivariate logistic regression analyses, conditional on all baseline covariates listed in Table 1 . The results of the propensity score models about the probabilities of the use of antiplatelet agents and warfarin are shown in Table I in the online-only Data Supplement. After that, we matched patients in the antiplatelet agent group to those in the no antithrombotic therapy group with a 1:1 ratio on the basis of the closest propensity score for the use of antiplatelet agents within a threshold of ±0.01 using the greedy algorithm. If >1 patient in the no antithrombotic therapy group could be matched to the corresponding subject in the antiplatelet agent group, 1 patient from the no antithrombotic therapy group was selected randomly without repeat sampling. Similar matching processes were performed for the comparisons of warfarin versus no antithrombotic therapy based on the propensity scores
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for the use of warfarin. Figures I and II in the online-only Data Supplement show the distributions of propensity scores of study subjects for the use of antiplatelet agents and warfarin before and after the propensity match, respectively.
Statistical Analysis
Data were presented as the mean value and SD for continuous variables and proportions for categorical variables. Differences between continuous values were assessed using the unpaired 2-tailed t test or 1-way ANOVA when the comparisons of 3 groups were performed. Differences between nominal variables were compared by the χ 2 test. The incidences of ischemic stroke and ICH were calculated by dividing the number of events by person time at risk. The risk of ischemic stroke and ICH was assessed using the Cox regression analysis. The proportional hazards assumption was tested using the Schoenfeld residual test, which showed no nonproportionality. Because of the high mortality rate in patients ≥90 years of age, competing-risk regression using the Fine and Gray model was also performed. 20 The year group (1996-1999, 2000-2003, 2004-2007, and 2008-2011) of patient enrollment was adjusted in the adjusted Cox regression and competing risk models. All statistical significances were set at P<0.05.
The present study was approved by the Institutional Review Board at Taipei Veterans General Hospital, Taipei, Taiwan. The Institutional Review Board agreed that the informed consent of subjects was not required because the present study was performed using Taiwan NHIRD, and the original identification numbers of subjects have been encrypted.
RESULTS
Clinical Characteristics of Patients in the Era Without NOACs (1996-2011)
In the era without NOACs (1996-2011), we included 15 756 patients with AF ≥90 years of age in our analysis: 11 064 on no antithrombotic therapy, 4075 on antiplatelet therapy, and 617 on warfarin. We compared 11 064 patients with AF to 14 658 patients without AF ≥90 years of age without antithrombotic therapy ( Table 1 ). The mean age of the whole cohort was 92.6 years (SD=2.7), with 39.2% male, and the mean CHA 2 DS 2 -VASc score was 5.3.
Patients on no antithrombotic therapy tended to be older, but the mean CHA 2 DS 2 -VASc score was lower than for those taking antiplatelet agents or warfarin. There were significant differences in various comorbidities: hypertension, diabetes mellitus, heart failure, prior stroke/transient ischemic attack, and vascular disease were less prevalent among patients on no antithrom- Two study cohorts identified from the NHIRD during different time periods were utilized for different analyses: (1) Era without NOACs (1996-2011). A total of 15 756 patients with AF ≥90 years of age were identified and divided into 3 groups based on the medications used for stroke prevention. The risk of ICH and the benefit of stroke risk reduction were analyzed between the different groups. The risks of ischemic stroke and ICH were also compared between patients with or without AF ≥90 years of age who did not receive antithrombotic therapies. (2) Era with NOACs (2012-2015). Because NOACs were only available in Taiwan from 2012, the comparisons of warfarin and NOACs were performed among patients with AF ≥90 years of age identified from the NHIRD between 2012 and 2015. A total of 768 and 978 newly diagnosed patients with AF ≥90 years received warfarin and NOACs for stroke prevention, respectively. The risks of ischemic stroke and ICH were compared between these 2 treatment groups. AF indicates atrial fibrillation; ICH, intracranial hemorrhage; NHIRD, National Health Insurance Research Database; and NOAC, nonvitamin K antagonist oral anticoagulant.
Impact of Antithrombotic Therapies on Ischemic Stroke and ICH
Among patients with AF, when compared with those taking no antithrombotic therapy as the reference population, elderly patients with AF taking antiplatelet agents showed no significant difference in ischemic stroke (386/4075, 5.04%/y versus 742/11 064, 5.75%/y; adjusted HR, 0.91; 95%, CI 0.80-1.04), whereas those taking warfarin were associated with a lower risk of ischemic stroke (39/617, 3.83%/y versus 742/11 064, 5.75%/y; HR, 0.65; 95% CI, 0.47-0.91) (Figure 2 and Table II in the online-only Data Supplement). There were 6886, 2013, and 258 mortality outcomes in the nontreatment, antiplatelet agents, and warfarin groups, respectively. After adjustment for the competing risk of death, the use of warfarin was still associated with a lower risk of ischemic stroke (HR, 0.69; 95% CI, 0.49-0.96) (Figure 2 and Table II in the onlineonly Data Supplement). *P value between groups with different strategies for stroke prevention (no antithrombotic therapy, antiplatelet agents, and warfarin). †P value for the comparisons between patients with or without AF who did not receive antithrombotic therapies. ‡Major bleeding was defined as ICH or bleeding from the gastrointestinal, genitourinary, or respiratory tract requiring hospitalization within 1 year before the patients were enrolled.
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When compared with those taking no antithrombotic therapy as the reference population, there was no significant difference in ICH risk among elderly patients with AF taking antiplatelet agents or warfarin. The nonsignificant difference persisted even after adjustment for the competing risk of death for both antiplatelet agents and warfarin ( Figure 2 and Table II in the onlineonly Data Supplement). The results of Cox regression analyses, which considered age as a time scale, are shown in Table III in the online-only Data Supplement) and are consistent with our principal findings.
Net Clinical Benefit
The NCB of antithrombotic strategies balancing stroke reduction against a weighted risk of serious bleeding (with ICH) was assessed with different weights from prior studies. When compared with no antithrombotic therapy or antiplatelet drugs as the reference groups, warfarin was associated with a positive NCB irrespective of definition applied (Table 3) .
Propensity-Matched Analysis
Given the baseline differences in demographics and comorbidities, we performed a propensity-matched analysis. Table IV in the online-only Data Supplement shows the comparability between AF cohorts on no antithrombotic therapy versus antiplatelet therapy (n=4075) and versus warfarin (n=617).
There were no significant differences between no antithrombotic therapy and antiplatelet drugs for ischemic stroke or ICH (Figure 2 and Table V in 
Sensitivity Analyses
Serial sensitivity analyses were performed by excluding patients who experienced both ischemic stroke and ICH (37 in AF and 32 in non-AF groups) from the analyses. The baseline characteristics of patients after excluding subjects who experienced both ischemic stroke and ICH are shown in Table VII in the online-only Data Supplement. The results of sensitivity analyses were generally consistent with those of the main analyses (Tables VIII,  IX , and X in the online-only Data Supplement).
NOACs Compared With Warfarin Among Patients With AF ≥90 Years of Age in the Era With NOACs (2012-2015)
From 2012 to 2015, 768 patients with AF ≥90 years of age treated with warfarin and 978 patients treated with NOACs (dabigatran in 361, rivaroxaban in 557, and apixaban in 60) were identified from the NHIRD. Baseline characteristics of patients treated with warfarin or NOACs are shown in Table 4 . Compared with patients taking warfarin as the reference population, patients with AF ≥90 years of age taking NOACs were associated with a lower risk of ICH (4/978, 0.42%/y versus 
DISCUSSION Main Findings
As far as we are aware, this is the largest observational cohort of very elderly (≥90 years of age) patients with AF, in which the use of antithrombotic strategies for stroke prevention were investigated. Our principal Compared with no treatment, antiplatelet agents showed no significant difference in ischemic stroke or ICH, but those taking warfarin were associated with a lower risk of ischemic stroke, with no difference in ICH risk. The results were similar in competing risk analysis for mortality and propensity match analysis. AF indicates atrial fibrillation; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICH, intracranial hemorrhage; and NOAC, nonvitamin K antagonist oral anticoagulant. +Adjusted for age, sex, CHA 2 DS 2 -VASc score (congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65-74, female), COPD, hyperlipidemia, malignancy, autoimmune diseases, liver cirrhosis, end-stage renal disease, and major bleeding. #Adjusted for age, sex, CHA 2 DS 2 -VASc score, COPD, hyperlipidemia, malignancy, autoimmune diseases, liver cirrhosis, end-stage renal disease, and major bleeding, with mortality being the competing risk. 
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findings are as follows: (1) the risk of ischemic stroke was higher in patients with AF, which persisted even in an adjusted model for mortality being a competing risk compared with patients without AF; (2) ICH risk was not significantly different between patients with or without AF; (3) antiplatelet agents showed no significant difference in ischemic stroke or ICH, but those taking warfarin were associated with a lower risk of ischemic stroke (by 31% in a competing risk model), with no difference in ICH risk; (4) when compared to no antithrombotic therapy or antiplatelet drugs as the reference groups, warfarin was associated with a positive NCB, and these findings persisted even in a propensity-matched analysis; and (5) compared with warfarin, NOACs were associated with a lower risk of ICH (by 68% in a competing risk model), with no difference in risk of ischemic stroke. Very elderly patients ≥90 years of age are underrepresented in RCTs, and even the largest prospective RCT in elderly subjects (BAFTA) only had modest numbers (≈10%) of subjects ≥90 years of age.
2 Overall, BAFTA clearly showed that warfarin was superior to aspirin for reducing thromboembolism, with no significant difference in major bleeds or ICH between warfarin and aspirin. In the subgroup analysis, there was no significant interaction for the efficacy or safety of warfarin versus aspirin, even at ≥85 years of age. 2 Elderly patients (especially the extreme elderly, ≥90 years of age) are often left untreated or given aspirin, even in contemporary studies such as the EORP-AF registry (EURObservational Research Programme-Atrial Fibrillation Pilot Registry). 21 Our data support BAFTA and show that antiplatelet agents are ineffective for stroke prevention and are not any safer than no antithrombotic therapy. In contrast, warfarin was associated with a positive NCB, showing an advantage of OAC treatment over no antithrombotic therapy, which persisted even in our propensity-matched analysis. Whether the availability of NOACs would improve the NCB is uncertain, especially because the only RCT comparing a NOAC to aspirin (ie, AVERROES [Apixaban Versus ASA to Prevent Stroke In AF Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment]) included a minority of very elderly patients. 22 A metaanalysis of the NOAC trials focused on elderly subjects (although only a minority would have been ≥90 years of age) showed that the efficacy and safety of NOACs versus warfarin was maintained, even in the elderly subjects. Indeed, NOACs did not cause excess bleeding and were associated with equal or greater efficacy than conventional therapy. 23 In our analysis, we showed that the risk of ischemic stroke was similar between patients with AF ≥90 years of age treated with warfarin or NOACs, but the risk of ICH was substantially lower with NOACs. ORIGINAL RESEARCH
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Further study with larger patient numbers and longer follow-up duration would be necessary to comprehensively investigate the safety and efficacy of NOACs compared with warfarin among elderly patients with AF ≥90 years of age. Of the observational cohorts, the Loire Valley AF project reported that elderly patients with AF (n=386, ≥90 years of age) did have a higher risk of stroke and bleeding, but the benefits of vitamin K antagonist therapy for stroke/thromboembolism or mortality were present regardless of increasing age. 24 In the Darlington AF registry, the majority of very elderly patients with AF (n=561 who were ≥85 years of age) in general practice do not receive OAC despite their higher stroke risk, and almost 50% received antiplatelet monotherapy. 25 The results of the Darlington AF registry showed that antiplatelet therapy use independently increased the risk of stroke, and there was a significant reduction in all-cause mortality with OAC therapy (odds ratio, 0.59; 95% CI, 0.36-0.99). 25 Of Asian cohorts, we are only aware of the analysis from the Fushimi AF registry, which found that Japanese extreme elderly patients (n=479, ≥85 years of age) with AF had a higher incidence of stroke but similar major bleeding risks compared with the younger AF population. It is interesting to note that OAC-treated patients had higher stroke rates compared with nonanticoagulated patients. 26 In the present study, we demonstrated that even among very elderly (≥90 years of age) patients, AF was still an important risk factor of ischemic stroke even after considering mortality as the competing risk. Therefore, stroke prevention remains the cornerstone for the management of AF among the nonagenarians. In our analysis, only 3.9% of patients ≥90 years of age received warfarin in the era without NOACs, and the proportion was 16.1% (7.1% with warfarin and 9.0% with NOACs) in the era with NOACs. The increment in the prescriptions of OACs could be partly attributable to the introduction of NOACs, which provide a more convenient choice other than warfarin because routine monitoring is not necessary with fewer drug-drug and drug-food interactions. The number of patients treated with warfarin during the 4-year period in the era with NOACs (n=768) was also larger than that of the 16-year period in the era without NOACs (n=617), and this observation may be partly explained by the increasing awareness about stroke prevention in AF. Our study focuses on the very elderly (≥90 years of age), where data were previously limited, and suggests that OACs may be considered Compared with patients taking warfarin as the reference population, patients with AF ≥90 years of age taking NOACs were associated with a lower risk of ICH, with no significant difference in ischemic stroke or major bleeding in each model. Major bleeding was defined as ICH or bleeding from the gastrointestinal, genitourinary, or respiratory tract requiring hospitalization. AF indicates atrial fibrillation; CI, confidence interval; ICH, intracranial hemorrhage; and NOAC, nonvitamin K antagonist oral anticoagulant. +Adjusted for congestive heart failure, malignancy, and major bleeding. #Adjusted for congestive heart failure, malignancy, and major bleeding, with mortality being the competing risk.
for stroke prevention given the significant stroke risk reduction and the positive NCB.
Study Limitations
Our study was the largest population-based study to investigate the use of OACs among patients with AF ≥90 years of age, and the strength of our study was the use of a nationwide dataset, which enrolled a large sample of subjects. However, there are still some limitations in our study. First, only 3.9% of patients ≥90 years of age received warfarin in the era without NOACs, and thus these patients may only represent the healthiest of the nonagenarians. Although we have performed the propensity match analysis to adjust for the baseline differences between different treatment groups, we can only report an association between the use of warfarin and the lower risk of ischemic stroke rather than causation. Because the present study was an observational study rather than a randomized trial, the presence of selection bias is highly probable, which could confound the analyses, especially for the comparisons of warfarin and nontreatment for the risk of ICH. Second, the information about international normalized ratio and the time in therapeutic range for warfarin was lacking in this nationwide registry. In the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), the time in therapeutic range for warfarin was only 44% in Taiwan. 27 Because a higher time in therapeutic range is significantly associated with a lower risk of ischemic stroke and ICH for patients with AF receiving warfarin, 28 the benefits of warfarin use for patients with AF ≥90 years of age could be even better if the time in therapeutic range was higher. Third, data on frailty or multiple falls were not available. However, a history of falls per se is not a contraindication to OACs. 29, 30 Fourth, we were not able to report the HAS-BLED score (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol) 31 for each patient because details on the amount of alcohol intake and biochemical indices of renal/liver function, which should be used to calculate the score, were not available in this registry database. However, decision making about use of OACs should be based on the CHA 2 DS 2 -VASc score, and a high bleeding risk score should not be used to exclude patients from OAC therapy. Rather, it allows clinicians to think of the correctable and treatable risk factors for bleeding. 32 Therefore, the lack of data on the HAS-BLED score may not significantly interfere with the interpretation of our study. Fifth, despite the large number of subjects enrolled in the present study, the number of patients treated with warfarin and the number of ICH events were small. Consequently, the possibility of type II (false-negative) errors cannot be ruled out, and further detailed analyses of the competing risk analysis, such as the subdistribution hazard and cause-specific hazard models, were not performed. The statistically insignificant increased risk of ICH with warfarin compared with no treatment (HR, 1.26; 95% CI, 0.70-2.25 in the competing risk model and HR, 1.46; 95% CI, 0.58-3.71 in the propensity match model) could be explained by the small event numbers, given the wide 95% CI. Last, the present study only enrolled Chinese patients, and whether the results can be extrapolated to other populations whose risk of stroke and ICH may be different remains uncertain.
CONCLUSIONS
In the largest observational cohort of very elderly (≥90 years of age) patients with AF, we show that antiplatelet agents showed no significant difference in ischemic stroke or ICH, but those taking warfarin were associated with a lower risk of ischemic stroke, with no difference in ICH risk. Compared with warfarin, NOACs were associated with a lower risk of ICH. Thus, OACs may still be considered as thromboprophylaxis for elderly patients, with NOACs being the more favorable choice.
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